logo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire6 days ago
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025.
Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Peloton Just Shocked Wall Street -- And It's Not About a New Bike
Peloton Just Shocked Wall Street -- And It's Not About a New Bike

Yahoo

time25 minutes ago

  • Yahoo

Peloton Just Shocked Wall Street -- And It's Not About a New Bike

Peloton (NASDAQ:PTON) shares jumped by nearly 12% at 8.53am in premarket after the company posted a surprise profit and rolled out a tighter cost-control strategy that could reshape its post-COVID narrative. CEO Peter Sternwho joined in January after a stint at Fordhas been aggressively reshaping the business to combat sluggish demand for its high-end bikes and treadmills. That effort appears to be gaining momentum. Q4 revenue came in at $606.9 million, beating analyst estimates of $579.8 million. Even more notably, earnings landed at 5 cents per share, ahead of the expected 6-cent loss. Warning! GuruFocus has detected 7 Warning Signs with PTON. Signs of operational progress are emerging across the board. Peloton plans to cut 6% of its global workforce, relocate select offices, and slash indirect costsmoves that could save $100 million over the next fiscal year. The company's focus on profitability is already showing up in the numbers: operating expenses dropped 20% year over year, and general and administrative costs were down 33%. Gross margin from connected fitness products improved by 900 basis points to 17.3%, helping drive a 96% increase in gross profit for the segment. These improvements suggest Stern's playbook may be starting to deliver. Looking ahead, Peloton expects fiscal 2026 revenue to land between $2.4 billion and $2.5 billionslightly ahead of the $2.41 billion Wall Street was modeling, according to LSEG. However, the company flagged a potential $65 million hit to free cash flow due to tariffs and said it plans to offset that through price adjustments. While the road back to growth may still have hurdles, investors may view this update as a meaningful step forward. The turnaround story isn't done, but it's no longer on pause. This article first appeared on GuruFocus. Sign in to access your portfolio

Why Shares of Nebius Group Are Skyrocketing Today
Why Shares of Nebius Group Are Skyrocketing Today

Yahoo

time25 minutes ago

  • Yahoo

Why Shares of Nebius Group Are Skyrocketing Today

Key Points Nebius Group reported strong second-quarter financial results. Management upwardly revised the annualized revenue run rate forecast for the end of 2025. With Nebius stock soaring in 2025, investors looking for cloud computing exposure may prefer an ETF at this point. 10 stocks we like better than Nebius Group › Investors have their heads in the clouds today -- or rather, they have their minds on a leading cloud stock. Nebius Group (NASDAQ: NBIS), developer of a cloud platform uniquely suited for artificial intelligence (AI) computing, announced second-quarter 2025 earnings, and investors are thrilled with the results. As of 10:27 a.m. ET on Thursday, shares of Nebius were up 24.5%. It's not only beating analysts' estimates that has investors excited Beating analysts' expectations for $101.2 million on the top line, Nebius posted second-quarter revenue of $105.1 million. Similarly, the company reported a $0.38 loss per share, narrower than the $0.42 loss per share that one analyst had been expecting. But it's management's outlook for the remainder of 2025 that has investors particularly excited. Because of what it credited in its letter to shareholders as "strong momentum," management upwardly revised the annualized revenue run-rate guidance for the end of 2025 to a range of $900 million to $1.1 billion from the original projection of $750 million to $1 billion. Addressing the company's strong prospects, CEO Arkady Volozh said: "Demand for AI infrastructure -- compute, software and services -- is only going to get stronger as use cases multiply. We are aggressively scaling up capacity to capture this substantial opportunity and are in the process of securing more than 1 GW of power by the end of 2026." Is it too late to buy this AI hyperscaler after today? It's not only semiconductor companies like Nvidia and Taiwan Semiconductor Manufacturing that investors are focusing on for AI exposure; they have recognized the appeal of AI hyperscalers like Nebius, which provide the crucial backbone for AI computing to occur. Shares have soared more than 140% since the start of the year, and they may be running out of room to race higher. For those who are eager to buy Nebius stock, it may be better to sit on the sidelines for the time being or consider a cloud computing exchange-traded fund to take a more conservative approach. Do the experts think Nebius Group is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nebius Group make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.26%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $635,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,099,758!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Scott Levine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Nebius Group. The Motley Fool has a disclosure policy. Why Shares of Nebius Group Are Skyrocketing Today was originally published by The Motley Fool Sign in to access your portfolio

Up, up and away: Firefly Aerospace has huge IPO as investors nab part of the space economy
Up, up and away: Firefly Aerospace has huge IPO as investors nab part of the space economy

Business Journals

time26 minutes ago

  • Business Journals

Up, up and away: Firefly Aerospace has huge IPO as investors nab part of the space economy

An Austin area aerospace company went public on the Nasdaq on Aug. 7. In this story, we explore how the company's price per share continued to increase in the past couple weeks as it notched more big wins. The article includes insights about how the company celebrated in New York and Texas, as well as comments from a Nasdaq leader on what this big IPO may mean for the broader market.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store